SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Borst P, Evers R, Kool M, et al. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92: 1295302.
  • 2
    Silverman JA. Multidrug-resistance transporters. Pharmacol Biotechnol 1999;12: 35386.
  • 3
    Larsen AK, Escargueil AE, Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 2000;85: 21729.
  • 4
    Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol 1999;187: 12737.
  • 5
    Blagosklonny MV. Cell death beyond apoptosis. Leukemia 2000;14: 15028.
  • 6
    Foster JR. Cell death and cell proliferation in the control of normal and neoplastic tissue growth. Toxicol Pathol 2000;28: 4416.
  • 7
    Rath PC, Aggarwal BB. TNF-induced signaling in apoptosis. J Clin Immunol 1999;19: 35064.
  • 8
    Mayo MW, Baldwin AS. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 2000;270: M55M62.
  • 9
    Higuchi M, Aggarwal BB. TNF induces internalization of the p60 receptor and shedding of the p80 receptor. J Immunol 1994;152: 35508.
  • 10
    Gross A, Yin XM, Wang K, et al. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999;274: 115663.
  • 11
    Giri DK, Aggarwal BB. Constitutive activation of NF-kB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. J Biol Chem 1998;273: 1400814.
  • 12
    Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kB transcription factor. Oncogene 1999;18: 691024.
  • 13
    Doi TS, Marino MW, Takahashi T, et al. Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc Natl Acad Sci USA 1999;96: 29949.
  • 14
    Wang C-Y, Cusack JC, Liu R, et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999;5: 4127.
  • 15
    Javelaud D, Wietzerbin J, Delattre O, et al. Induction of p21waf1/cip1 by TNFα requires NF-κB activity and antagonizes apoptosis in Ewing tumor cells. Oncogene 2000;19: 618.
  • 16
    Shao R, Hu MC, Zhou BP, et al. E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IkappaB kinases and nuclear factor kappaB activities. J Biol Chem 1999;274: 2149598.
  • 17
    Patel D, Huang S-M, Baglia LA, et al. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J 1999;18: 506172.
  • 18
    Wadgaonkar R, Phelps KM, Haque Z, et al. CREB-binding protein is a nuclear integrator of nuclear factor-κB and p53 signaling. J Biol Chem 1999;274: 187982.
  • 19
    De Bosscher K, Berghe WV, Vermeulen L, et al. Glucocorticoids repress NF-kBdriven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Science USA 2000;97: 391924.
  • 20
    Valenti M, Cimoli G, Parodi S, et al. Potentiation of Tumor Necrosis Factor-mediated cell killing by VP16 on human ovarian cancer cell lines. [“in vitro” results and clinical implications]. Eur J Cancer 1993; 29A: 115761.
  • 21
    Valenti M, Cimoli G, Mariani GL, et al. Potentiation of TNF-mediated cell killing by Mitoxantrone: relationship to DNA single-strand breaks formation. Biochem Pharmacol 1993;46: 1199206.
  • 22
    Debernardis D, Stanzione S, Ottoboni C, et al. Endogenous TNF enhances topoisomerase II inhibitors activity in human ovarian cancer cell lines. J Pharmacol Exp Ther 1996;279: 8490.
  • 23
    Vikhanskaya F, Vignati S, Beccaglia P, et al. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to taxol by inducing G2 arrest and apoptosis. Exp Cell Res 1998;241: 96101.
  • 24
    Cimoli C, Valenti M, Ottoboni C, et al. HPV-16-E6 enhances mitoxantrone sensitivity in a human ovarian cancer cell line: an isolated instance or a trend? Int J Oncol 2001;in press.
  • 25
    Fan S, Chang JK, Smith ML, et al. Cell lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustrd. Oncogene 1997;14: 212736.
  • 26
    Russo P, Ottoboni C, Crippa A, et al. The non peptidomimetic farnesyltransferase inhibitor RPR-115135 increases cytotoxicity of 5-FU: role of p53. J Pharmacol Exp Ther 2001;in press.
  • 27
    Ottoboni C, Crippa A, Falugi C, et al. Induction of micronuclei by a new nonpeptidic mimetic farnesyltransferase inhibitor RPR-115135: role of gene mutations. Mutagenesis 2001;16: 1. 23–4.30.
  • 28
    Debernardis D, Graniela Sirè E, de Feudis P, et al. p53 status does not affect sensitivity of human ovarian cancer cell lines to Paclitaxel. Cancer Res 1997;57: 87074.
  • 29
    Bertrand R, Pommier Y. Assessment of DNA damage in mammalian cells by filter elution methodology in cell growth and apoptosis: a pratical approach. In: Studzinski GP, ed. Oxford: Oxford University Press, 1996. 97117.
  • 30
    Russo P, Poggi L, Parodi S, et al. Production of protein-associated DNA breaks by 8- methoxycaffeine, caffeine and 8-chlorocaffeine in isolated nuclei from L1210 cells: comparison with those produced by topoisomerase II inhibitors. Carcinogenesis 1991;12: 178190.
  • 31
    Bossy-Wetzel E, Green DR. Assays for cytochrome c release from mitochondria during apoptosis. Methods Enzymol 2000;32: 2357.
  • 32
    Vikhanskaya F, Clerico L, Valenti M, et al. Mechanism of resistance to cisplatin in a human ovarian carcinoma cell line selected for resistance to Doxorubicin. Possible role of p53. Int J Cancer 1997;72: 1559.
  • 33
    Shreiber E, Matthias P, Muller MM, et al. Rapid detection of octamer binding proteins with “mini-extracts”, prepared from a small number of cell. Nucl Acids Res 1989;15: 641921.
  • 34
    Jee S-H, Shen S-H, Chiu H-C, et al. Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 2001;20: 198208.
  • 35
    Rapp L, Chen JJ, The papillomavirus E6 proteins. Biochim Biophys Acta 1998;1378: F1F19.
  • 36
    Von Ahsen O, Waterhouse NJ, Kuwana T, et al. The “harmless” release of cytochrome c. Cell Death Diff 2001;7: 11929.
  • 37
    Zimmermann H, Degenkolbe R, Bernard HU, et al. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J Virol 1999;73: 620919.
  • 38
    Woodworth CD, Simpson S. Comparative lymphokine secretion by cultured normal human cervical keratinocytes, papillomavirus-immortalized, and carcinoma cell lines. Am J Pathol 1993;142: 154455.